CCL2 and prostate carcinoma: Furthermore, prostate cancer patients enrolled in a phase II clinical trial using an anti-CCL2 monoclonal antibody showed an increased CCL2 release following anti-CCL2 interruption [101], suggesting that a continuous arrest of CCL2 is mandatory to control tumour progression.